BGPT: Paper Review: Targeting activated IL-23 signaling in Scleroderma by tildrakizumab

Explore by Goal

Quick Explanation Copied

Core claim: This paper reports that IL-23 is elevated in SSc skin and that blocking IL-23 with the p19-targeting antibody tildrakizumab reverses (in mice) bleomycin-induced skin and lung fibrosis while reducing inflammatory infiltration and pSTAT3 signaling.

Skeptical take (main caveats): Human data are correlational (IL-23 vs MRSS), the dominant fibrosis model is bleomycin (which does not fully recapitulate all features of human SSc), and key sample sizes appear modest—so effect estimates and generalizability should be treated cautiously until corroborated in larger clinical studies.

Long Explanation

Paper Review (Evidence-First): Targeting activated IL-23 signaling in Scleroderma by tildrakizumab

Date context: March 21, 2026 (user provided)

What the paper set out to test

The study asks whether IL-23 signaling is implicated in SSc fibrosis and whether pharmacologic IL-23 blockade with tildrakizumab can prevent or reverse fibrotic outcomes in vivo, while also examining IL-23 in human SSc skin.

Mechanism map (paper’s stated pathway)

Context: IL-23 is described as a heterodimeric cytokine (p19/p40) that signals through IL-23R to activate a JAK2/STAT3 pathway; the paper operationalizes this by measuring pSTAT3 as a downstream readout of “activated IL-23 signaling” in tissues. Broader background (non-paper): IL-23/IL-17 pathway mechanisms and genetic/therapy connections are reviewed in the cited literature.

Panel A — Human SSc: IL-23 elevation & association with severity

The paper reports higher IL-23-positive signal in SSc skin versus healthy controls, with significant comparisons in early SSc (p=0.0025) and a non-significant/near-threshold p-value in late-stage SSc (p=0.0646) and a positive correlation between IL-23 and MRSS (p=0.0080).

Caveat: correlation does not establish causality in humans; IL-23 could be a marker of inflammatory activity rather than a causal driver of fibrosis.

Panel B — Mouse prevention model: fibrosis & STAT3 signaling outcomes

In the bleomycin prevention setting, dermal thickness increased versus PBS (p=0.0033) and was significantly reduced with the high-dose tildrakizumab regimen (30 mg/kg) (reported p=0.0425). Dermal collagen accumulation was also reduced (p=0.0136). In parallel, immunolabeling showed decreased procollagen+ fibroblasts (p<0.0001), αSMA+ myofibroblasts (p=0.0016), and CD45+ pan-leukocytes (p=0.0034) in the tildrakizumab group, and pSTAT3 was significantly lower (p<0.0001).

Skeptical point: multiple markers were changed, but the paper does not (from the provided text) show whether these effects are mediated specifically by IL-23→STAT3 in the relevant cell types (e.g., myofibroblasts vs immune subsets). Without cell-type-specific pathway validation, STAT3 changes could be downstream of broader inflammation changes.

Panel C — Mouse regression model: “reversal” vs “prevention” and lung findings

For regression, treatment starts on day 14 after bleomycin and continues until day 28; outcomes on day 30 include reduced lung collagen deposition, reduced αSMA+ myofibroblast accumulation, reduced CD45 infiltrate, reduced IL-23 signal, reduced F4/80+ macrophages, and reduced activated STAT3 (p=0.0017). Reported p-values include collagen deposition and multiple inflammatory readouts: IL-23 (p=0.0148), macrophages F4/80 (p=0.0225), activated STAT3 (p=0.0017), and CD45 (p<0.0001).

Important skeptical nuance: the paper’s wording emphasizes “regression,” but in a preclinical bleomycin system, “regression” can be partially due to effects on ongoing inflammation and remodeling rather than true reversal of established fibrosis architecture. The paper provides marker-level decreases (collagen, αSMA, inflammatory infiltrates) which are consistent with reduced fibrotic burden, but mechanistic proof of long-lived reversal requires longer follow-up and/or additional structural assays.

Relevance to IL-23 biology & fibrosis frameworks (context checks)

IL-23 biology is discussed as central to chronic inflammatory diseases and connects to Th17 differentiation and chronic inflammatory milieus via IL-23/IL-17 pathways. The paper’s mechanistic emphasis on JAK/STAT3 is consistent with literature linking STAT3 activation to skin fibrosis and TGF-β signaling.

This pipeline is evidence-connected to what the paper explicitly measures (IL-23 signal in biopsies; pSTAT3 decrease; collagen/αSMA decreases; CD45/F4/80 decreases).

Critical appraisal: key strengths & main blind spots

Strengths (from provided text)

Translational bridge: includes human IL-23 biopsy staining with correlation to MRSS, plus mechanistic downstream readout (pSTAT3) in mice.
Both prevention and regression paradigms: starts treatment at day 0 vs concurrent with bleomycin (prevention) and at day 14 (regression), which is important when assessing “reversal.”
Multi-level readouts: dermal thickness, hydroxyproline/collagen content, immunostaining for fibroblast/myofibroblast and immune infiltration markers, and a pathway phosphorylation readout.

Blind spots / limitations (important)

Human data are modest and correlational (IL-23 vs MRSS), so they support association but not causality.
Bleomycin model generalizability: the paper itself frames bleomycin as an “organ fibrosis model,” but bleomycin-induced fibrosis does not fully reproduce all immunopathologic and vascular features of human SSc.
Cell-type mediation not fully resolved: decreases in immune infiltration and pSTAT3 occur alongside fibrosis marker reductions, but the provided text does not show cell-type-specific IL-23R/STAT3 causal experiments.
Measurement/analysis transparency gap: the excerpt provided includes many p-values and mentions that imaging was done blinded, and analysis used ImageJ/Qupath, but the full details of sample sizes per each figure panel and raw effect sizes are not present in the excerpt.

Follow-up analyses you can run on BGPT

Link to author-specific BGPT reviews

Feedback:

Updated: March 21, 2026